Seqens SAS
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Seqens SAS - overview
Established
2003
Location
Lyon, -, France
Primary Industry
Chemicals
About
Seqens SAS is a leading manufacturer of active pharmaceutical ingredients (APIs) and specialty ingredients for personal care products, serving a global clientele with innovative and tailored solutions. Founded in 2003 and headquartered in Lyon, France, Seqens SAS specializes in the production of active pharmaceutical ingredients and personal care ingredients. The company underwent a significant business change in December 2021 when SK Capital and Bpifrance acquired a majority stake from Ardian. The CEO of the company is Antoine Bertin.
As of the latest funding round, Seqens has raised a total of EUR 160. 00 mn through a Secondary Buyout involving investors such as Eurazeo and Merieux Equity Partners. Seqens specializes in the manufacture of a diverse range of ingredients tailored for the pharmaceutical and personal care industries. Their core product offerings include generic and custom active pharmaceutical ingredients (APIs), intermediates, and excipients that serve as essential components in drug formulation and development.
In the personal care sector, Seqens provides specialized ingredients aimed at enhancing cosmetic formulations, focusing on innovative solutions to address consumer needs. The company serves over 1,500 customers across more than 80 countries, including major markets in North America, Europe, and Asia, and is committed to continuous research and development to enhance its product portfolio. In 2022, Seqens reported a revenue of EUR 21,204,541. 40, with an EBITDA of EUR -17,797,609.
60. The company engages in B2B transactions primarily with pharmaceutical companies and personal care manufacturers, supplying bulk ingredients based on negotiated pricing structures. Seqens plans to leverage the capital raised in December 2021 to strengthen its position in the pharmaceutical and specialty ingredients markets. The company is focused on developing new products tailored to evolving consumer needs, although specific release dates have not been disclosed.
Furthermore, Seqens aims to expand its market presence, particularly targeting growth in regions such as Asia and North America over the coming years.
Current Investors
Ardian, Eurazeo, Bpifrance
Primary Industry
Chemicals
Sub Industries
Specialty Pharmaceuticals, Commodity Chemicals
Website
www.seqens.com
Verticals
Manufacturing
Company Stage
Buyout
Total Amount Raised
Subscriber access only
Seqens SAS - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Corporate Carve Out, Trade Sale | Completed | Seqens SAS' Botanical Actives and In-Vitro Diagnostics activity | - | ||||||||
| Secondary Buyout | Completed | Seqens SAS | - | ||||||||
| Corporate Carve Out | Completed | Humens Group | - | ||||||||
| Add-on | Completed | PCI Synthesis, Inc. | - | ||||||||
| Add-on, Trade Sale | Completed | Chemoxy International Ltd. | - |
Displaying 1 - 5 of 15
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.